| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00449605 2006-005385-39 Details | 2016-05-16 Interventional | 3 | 508 | Glimepiride Metformin Rimonabant Diabetes Mellit… | Company decision taken in light of demands by certain national health authorities - | |||
| NCT02689401 Details | 2016-05-13 Interventional | 1 | 0 | Ferrosoferric O… Esophageal Neop… Esophageal Canc… | Awaiting additional safety data - | |||
| NCT02529514 Details | 2016-05-13 Interventional | 4 | - | Baclofen Sleep | - - | |||
| NCT02506855 Details | 2016-05-13 Interventional | 3 | 0 | Ropivacaine Postoperative N… Vomiting Postoperative P… | The investigator decided not to continue the study. - | |||
| NCT02501278 2015-004602-42 Details | 2016-05-13 Interventional | 2 | 0 | Cisplatin Uterine Cervica… | company (Inovio) is no longer able to support the study - | |||
| NCT01949870 Details | 2016-05-13 Interventional | 1 | 6 | Gemcitabine Biliary Tract N… Inoperable Loca… | change in the development strategy Dose escalation stopped after the first cohort due to changes in the drug development strategy. As such, a non-tolerated dose was not determined and the maximum tolerated dose could not be confirmed. | |||
| NCT01807286 Details | 2016-05-13 Interventional | 1 | 3 | Dexamethasone Melphalan Pomalidomide Amyloidosis Immunoglobulin … Myeloma | Sponsor requested termination - | |||
| NCT01289938 2008-003778-16 Details | 2016-05-13 Interventional | 1 | 49 | Diphenhydramine Metoclopramide Promethazine Metabolism, Inb… Drug Metabolism… | To unsuccessful recruitment of rare UM-genotype. All other planned genotype groups are
completed (EM, IM and PM). - | |||
| NCT01202110 Details | 2016-05-13 Interventional | 2 | 10 | Propranolol Brain Injuries Brain Injuries,… Wounds and Inju… Traumatic Brain… | - - | |||
| NCT00979576 Details | 2016-05-13 Interventional | 1 | 19 | Nintedanib Pemetrexed Carcinoma, Non-… | - The trial was planned to comprise of two parts, with the phase II being based on the results of another study. The other study was stopped early due to futility analysis therefore only phase I of the study was completed. | |||
| NCT02079480 Details | 2016-05-12 Interventional | 1 | 130 | Keyhole-limpet … Healthy Adult V… | - - | |||
| NCT01226823 Details | 2016-05-12 Interventional | 3 | 0 | Ursodeoxycholic… Cholestasis Cholestasis, In… Pregnancy Compl… Intrahepatic Ch… | Modified insurance requests by a new law released after its approval. - | |||
| NCT01091701 Details | 2016-05-12 Interventional | 1/2 | 0 | Plasma-lyte 148 Stroke | Business reasons - | |||
| NCT01963611 2013-002283-25 Details | 2016-05-11 Interventional | 2 | 255 | Glatiramer Acet… Multiple Sclero… Multiple Sclero… Sclerosis Relapsing Remit… | Study was terminated based on sponsor discretion. Based on Sponsor decision to discontinue the clinical development program of plovamer acetate therapy for multiple sclerosis the trial was prematurely terminated | |||
| NCT01717846 Details | 2016-05-11 Interventional | 4 | 0 | Abatacept Arthritis Arthritis, Rheu… Lymphocytosis Apoptotic DNA D… Rheumatoid Arth… T-cell Lymphocy… | The PI has left UCLA and we do not plan to pursue this study. - | |||
| NCT00892346 Details | 2016-05-10 Interventional | 3 | - | Melphalan Thalidomide Multiple Myelom… Neoplasms, Plas… | No avaliability of melphlan in mainland China - | |||
| NCT02029417 Details | 2016-05-09 Interventional | 2 | 2 | Azacitidine Cytarabine Decitabine Homoharringtoni… Leukemia Leukemia, Eryth… Leukemia, Megak… Leukemia, Monoc… Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Myelodysplastic… Acute Myeloid L… Adult Acute Meg… Adult Acute Min… Adult Acute Mon… Adult Acute Mon… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Erythrole… Adult Pure Eryt… Secondary Acute… Untreated Adult… | Major revisions needed in study Due to the study's early termination and low accrual no statistical inference of the primary aims were carried forth. | |||
| NCT01452100 2010-021467-33 Details | 2016-05-09 Interventional | 2 | 39 | Prednisone Embolism Embolism, Chole… Cholesterol Emb… | Inclusion default - | |||
| NCT00567879 2007-002449-19 Details | 2016-05-09 Interventional | 1/2 | 56 | Panobinostat Trastuzumab Breast Neoplasm… Breast Cancer | The study was terminated early due to insufficient evidence of clinical benefit. - | |||
| NCT02762253 Details | 2016-05-05 Interventional | 2 | 320 | Riboflavin Keratoconus | No IND submitted to the FDA - |